434 related articles for article (PubMed ID: 11436584)
41. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
[TBL] [Abstract][Full Text] [Related]
42. A case with two unusual findings: cutaneous leishmaniasis presenting as panniculitis and pericarditis after antimony therapy.
Eryilmaz A; Durdu M; Baba M; Bal N; Yiğit F
Int J Dermatol; 2010 Mar; 49(3):295-7. PubMed ID: 20465667
[TBL] [Abstract][Full Text] [Related]
43. Visceral leishmaniasis and disseminated intravascular coagulation in a dog.
Font A; Gines C; Closa JM; Mascort J
J Am Vet Med Assoc; 1994 Apr; 204(7):1043-4. PubMed ID: 8045804
[TBL] [Abstract][Full Text] [Related]
44. Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.
Teva A; Porrozzi R; Oliveira-Neto MP; Grimaldi GJ
J Parasitol; 2005 Aug; 91(4):976-8. PubMed ID: 17089782
[TBL] [Abstract][Full Text] [Related]
45. [Glucantime injection: benefit versus toxicity].
Masmoudi A; Maalej N; Mseddi M; Souissi A; Turki H; Boudaya S; Bouassida S; Zahaf A
Med Mal Infect; 2005 Jan; 35(1):42-5. PubMed ID: 15695033
[TBL] [Abstract][Full Text] [Related]
46. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
47. [Nephrotic syndrome and acute pancreatitis related to glucantime administration].
Valencia ME; Laguna F; González Lahoz J
An Med Interna; 2000 Jan; 17(1):54. PubMed ID: 10730416
[No Abstract] [Full Text] [Related]
48. Short report: Contribution of quantitative real-time polymerase chain reaction to follow-up of visceral leishmaniasis patients treated with meglumine antimoniate.
Aoun K; Chouihi E; Amri F; Ben Alaya N; Raies A; Mary C; Bouratbine A
Am J Trop Med Hyg; 2009 Dec; 81(6):1004-6. PubMed ID: 19996428
[TBL] [Abstract][Full Text] [Related]
49. Pentavalent antimonial-induced torsade de pointes.
Ortega-Carnicer J; Alcázar R; De la Torre M; Benezet J
J Electrocardiol; 1997 Apr; 30(2):143-5. PubMed ID: 9141610
[TBL] [Abstract][Full Text] [Related]
50. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens.
Oliveira-Neto MP; Schubach A; Mattos M; Gonçalves-Costa SC; Pirmez C
Pathol Biol (Paris); 1997 Jun; 45(6):496-9. PubMed ID: 9309267
[TBL] [Abstract][Full Text] [Related]
51. PCR follow-up examination after treatment of canine leishmaniosis (CaL).
Steuber S; Moritz A; Schirrmann I; Greiner M
Tokai J Exp Clin Med; 1998 Dec; 23(6):285-92. PubMed ID: 10622624
[TBL] [Abstract][Full Text] [Related]
52. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil.
Oliveira AL; Brustoloni YM; Fernandes TD; Dorval ME; Cunha RV; Bóia MN
Trop Doct; 2009 Jul; 39(3):180-2. PubMed ID: 19535762
[TBL] [Abstract][Full Text] [Related]
53. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
Shazad B; Abbaszadeh B; Khamesipour A
Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
[TBL] [Abstract][Full Text] [Related]
54. Cutaneous lupoid leishmaniasis: a case report.
Ferahbaş A; Mistik S; Utaş S; Yaman O; Canoz O; Doganay M; Aşçioglu O
Cutis; 2006 Jan; 77(1):25-8; quiz 37-8. PubMed ID: 16475491
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of the cardiac toxicity of N-methyl-glucamine antimoniate in dogs with naturally occurring leishmaniasis.
Luciani A; Sconza S; Civitella C; Guglielmini C
Vet J; 2013 Apr; 196(1):119-21. PubMed ID: 23021954
[TBL] [Abstract][Full Text] [Related]
56. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection.
Hailu W; Weldegebreal T; Hurissa Z; Tafes H; Omollo R; Yifru S; Balasegaram M; Hailu A
Trans R Soc Trop Med Hyg; 2010 Nov; 104(11):706-12. PubMed ID: 20870258
[TBL] [Abstract][Full Text] [Related]
57. Comparison of Thymus vulgaris (Thyme), Achillea millefolium (Yarrow) and propolis hydroalcoholic extracts versus systemic glucantime in the treatment of cutaneous leishmaniasis in balb/c mice.
Nilforoushzadeh MA; Shirani-Bidabadi L; Zolfaghari-Baghbaderani A; Saberi S; Siadat AH; Mahmoudi M
J Vector Borne Dis; 2008 Dec; 45(4):301-6. PubMed ID: 19248657
[TBL] [Abstract][Full Text] [Related]
58. Early enlargement of an ulcerated area during leishmaniasis treatment with meglumine antimoniate in Brazil.
Romero GA; Molinet FJ; Noronha EF
Trans R Soc Trop Med Hyg; 2013 Apr; 107(4):266-8. PubMed ID: 23315614
[TBL] [Abstract][Full Text] [Related]
59. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study.
Esfandiarpour I; Dabiri SH
Int J Dermatol; 2007 Aug; 46(8):848-52. PubMed ID: 17651170
[TBL] [Abstract][Full Text] [Related]
60. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis.
Mohammad N; Sagheer F; Paracha MM; Khan AQ; Naseem S; Wasim M
J Ayub Med Coll Abbottabad; 2022; 34(4):849-853. PubMed ID: 36566412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
